Stock AnalizZoetis Inc. ZTS
Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026
Zoetis Inc. (ZTS) is a healthcare company listed in the US with a market value of about $34.1B. In the twelve months to September 30, 2026 it had revenue of $9.5B and net income of $2.5B, a net margin of 26.4%.
Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is value (4/5); the weakest is financial health (2/5).
Key numbers: a P/E of 14.1, a price to free cash flow of 15.2, 5-year revenue growth of 7% a year, a 5-year average ROIC of 21%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 21% below the current price.
Score: 3.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- 20% to 100% of free cash flow returned to shareholders
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.5B | $9.5B | $9.3B | $8.5B | $8.1B | $7.8B | $6.7B | $6.3B | $5.8B | $5.3B | $4.9B |
| Net income | $2.5B | $2.7B | $2.5B | $2.3B | $2.1B | $2.0B | $1.6B | $1.5B | $1.4B | $864M | $821M |
| Free cash flow | $2.2B | $2.3B | $2.3B | $1.6B | $1.3B | $1.7B | $1.7B | $1.3B | $1.5B | $1.1B | $497M |
| EPS (diluted) | $5.93 | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 | $3.11 | $2.93 | $1.75 | $1.65 |
| Net margin | 26.4% | 28.2% | 26.9% | 27.4% | 26.2% | 26.2% | 24.5% | 24.0% | 24.5% | 16.3% | 16.8% |
| ROIC | — | 22.4% | 23.0% | 21.3% | 18.1% | 19.5% | 16.3% | 17.9% | 18.0% | 14.2% | 15.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $89.69, 7% above the current price; targets range from $73.00 to $115.00; the consensus rating is “Buy”; expected EPS is $6.29 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Zoetis’s P/E ratio?
About 14.1, based on the last twelve months of diluted earnings per share (forward P/E about 14.2).
Is Zoetis stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 21% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Zoetis pay a dividend?
Yes. The dividend yield is about 2.57%, and it has paid dividends for 10 years in our data.
Is Zoetis a good stock to buy?
We do not give buy or sell advice. Zoetis scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.